Efficacy and safety of ticagrelor plus cilostazol in the treatment of patients with low body weight after percutaneous coronary intervention
10.3969/j.issn.1004-8812.2017.05.003
- VernacularTitle:替格瑞洛联合西洛他唑在经皮冠状动脉介入治疗术后低体重患者中抗血小板治疗的安全性和有效性
- Author:
Xi CHEN
;
Li SHI
;
Jun LI
;
Yuan ZHU
;
Tongguo WU
- Keywords:
Percutaneous coronary intervention;
Whole blood impedance aggregometry (WBIA);
Ticagrelor;
Cilostazol;
Acute coronary syndrome
- From:
Chinese Journal of Interventional Cardiology
2017;25(5):255-260
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of ticagrelor plus cilostazol of different dosage in the treatment of low-weight patients after PCI.Methods A total of 148 consecutive ACS patients (body weight ≤ 65 kg) past PCI and with aspirin intolerance were enrolled and randomly divided into four groups.Patients given cilostazol 50mg twice daily plus clopidogrel 75 mg daily were named as the CC50 mg group.Patients in the CC100 mg group were given cilostazol 100 mg twice daily plus clopidogrel 75 mg daily.The TCS0 mg group were given cilostazol 50 mg twice daily plus standard ticagrelor 90mg twice daily and the TC100 mg group were given cilostazol 50 mg twice daily plus standard ticagrelor 90 mg twice daily.All patients were followed up clinically for 6 months.The clinical endpoints were MACEs and bleeding events.Platelet aggregation at 7 and 30 days after treatment the incidence of clinical endpoints during followup were compared between the four groups.Results Patients in the TC100mg group had the lowest platelet aggregation rates tested on both the 7th and 30th day after treatment among all the 4 groups.After 6 months of follow up,the MACEs rate was not significantly different between the four groups (P =0.930).Bleeding events rates in the TC100 mg group the highest among the 4 but without groups significant differences.Conclusions In ACS patients with low body weight ≤ 65 kg) past PCI and with aspirin intolerance,cilostazol 50mg twice daily plus ticagrelor is a safe and efficacious therapeutic regimen.
